Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a Week-Long heart patch catch more hidden strokes?

NCT ID NCT05082467

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a water-resistant, wireless ECG patch worn for 7 days can detect more cases of hidden atrial fibrillation (a heart rhythm problem that raises stroke risk) than the usual 24-hour Holter monitor. Researchers will enroll 320 adults who recently had a stroke or mini-stroke of unknown cause. The goal is to see if the longer monitoring period leads to better detection and more appropriate blood-thinner use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
7-day wireless ECG patch
What this could lead to
If successful, this could show that a longer monitoring period with a comfortable patch finds more cases of hidden atrial fibrillation after a stroke, helping doctors decide on blood-thinning treatment to prevent another stroke.
What could go wrong
This is a single-center study with 320 participants, so results may not apply to all patients. The patch might not detect all cases, and the study does not test whether finding more AF actually reduces strokes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

320 people

The number who actually took part.

Started

Jan 2021

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients who are admitted with acute ischemic stroke or transient ischemic attack (TIA) of undetermined etiology after completion of a standard clinical stroke work-up will be included.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years. 2. Diagnosis of acute ischemic stroke or transient ischemic attack (TIA) (WHO definition) of undetermined etiology made by neurologist within 7 days after the index event. The event must be either: * an ischemic stroke confirmed by neuroimaging; or * a TIA, defined as involving a focal unilateral motor deficit, speech/language deficit or hemianopia, with symptom duration \<24 hours (note: amaurosis fugax/ transient monocular blindness, pure sensory spells, isolated vertigo spells, etc. do not qualify for enrolment given the potential for misdiagnosis of such events). 3. No AF detected in baseline 12-lead ECG on admission. 4. The following diagnostic test have already been completed as part of clinical routine post-stroke/TIA: * Brain imaging with CT or MRI, * Transthoracic echocardiography to congenital heart disease and endocarditis. 5. Recurrent stroke/TIA is inclusionary as long as patient meets inclusion/exclusion criteria for study enrolment. Exclusion Criteria: 1. Stroke of unknown time of symptom onset. 2. Modified Rankin Scale ≥5 on index admission. 3. Previous documented history of primary intracerebral bleeding. 4. Previous documented history of AF or atrial flutter (a remote history of transient AF during perioperative period is not exclusionary). 5. Skin allergies, conditions, or sensitivities to cardiac patch. 6. Exclusively retinal stroke or retinal TIA event. 7. Pre-existing indication for anticoagulation (eg. History of mechanical heart valve replacement, deep vein thrombosis). 8. Pre-existing contraindication for permanent anticoagulation (eg. hypocoagulable state). 9. Echocardiographic findings of congenital heart disease and endocarditis. 10. Indicated for pacemaker, implantable cardiac defibrillator (ICD), CRT device, or an implantable hemodynamic monitoring system. 11. Intravenous drug users (IVDUs). 12. Life expectancy \< 1 year for reasons other than stroke (eg. Metastatic cancer disease). 13. Concomitant participation in other clinical trials involving investigational medications. 14. Pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sarawak General Hospital

    Kuching, Sarawak, 93586, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.